Retinal vein occlusion (RVO) is a vision-threatening condition caused by blocked veins in the retina. If left untreated, RVO can significantly affect overall visual performance.
VABYSMO® (faricimab-svoa) is approved to treat RVO. It’s thought to block 2 causes of vision loss (VEGF and Ang-2),‡ proteins that drive abnormal blood vessel swelling, leakage, and growth. The benefit of blocking Ang-2 has yet to be established. It also improves vision quickly. On average, people with CRVO gained 13 letters at 1 month after their first treatment while people with BRVO gained 11 letters at 1 month after their first treatment on an eye chart with VABYSMO, similar to aflibercept 2 mg. On average, people with CRVO and BRVO gained and maintained 17 letters over 6 months on an eye chart with VABYSMO, similar to aflibercept 2 mg. VABYSMO is given by injection into the eye every 4 weeks for 6 months.
The possible serious side effects of VABYSMO were inflammation and detached retina (separation of the retina from the back of the eye); a temporary increase in eye pressure; although not common, there is a risk of a stroke or heart attack; severe inflammation of vessels in the retina. These are not all the possible side effects of VABYSMO.